Cardiovascular Therapeutics

Review Article

Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis

Table 2

Clinical outcome of the included studies.


Research/year	Maintenance regimen	NACE		MACE		All-cause death		Cardiac death		Ischemic stroke		Major bleeding		Stent thrombosis
Research/year	Maintenance regimen	Event	Total	Event	Total	Event	Total	Event	Total	Event	Total	Event	Total	Event	Total

HOST-EXAM trial/2021	Aspirin ()	207	2728	146	2728	36	2728	14	2728	26	2728	53	2728	16	2728
HOST-EXAM trial/2021	Clopidogrel ()	152	2710	99	2710	51	2710	19	2710	14	2710	33	2710	10	2710

CAPRIE/1996	Aspirin ()	ND	5843	283	5843	97	5843	ND	5843	42	5843	ND	5843	ND	5843
CAPRIE/1996	Clopidogrel ()	ND	5787	291	5787	111	5787	ND	5787	42	5787	ND	5787	ND	5787

THEMIS-PCI/2019	Aspirin ()	581	5596	480	5596	323	5596	183	5596	113	5596	101	5596	18	5596
THEMIS-PCI/2019	Ticagrelor ()	601	5558	404	5558	282	5558	174	5558	88	5558	197	5558	9	5558

GLOBAL LEADERS landmark-analysis/2022	Aspirin ()	310	5813	151	5813	66	5813	ND	5813	26	5813	17	5813	16	5813
GLOBAL LEADERS landmark-analysis/2022	Ticagrelor ()	236	5308	101	5308	51	5308	ND	5308	17	5308	28	5308	10	5308

ARCTIC-Interruption/2014	Aspirin ()	28	624	27	624	9	624	ND	624	4	624	1	624	3	624
ARCTIC-Interruption/2014	Aspirin plus clopidogrel ()	30	635	24	635	7	635	ND	635	6	635	7	635	0	635

DAPT/2014	Aspirin ()	357	4941	285	4941	74	4941	47	4941	34	4941	72	494	65	4941
DAPT/2014	Aspirin plus clopidogrel ()	340	5020	211	5020	98	5020	45	5020	24	5020	129	5020	19	5020

DES-LATE/2013	Aspirin ()	74	2514	57	2514	32	2514	19	2514	13	2514	24	2514	11	2514
DES-LATE/2013	Aspirin plus clopidogrel ()	89	2531	61	2531	46	2531	28	2531	15	2531	34	2531	7	2531

OPTIDUAL/2016	Aspirin ()	52	690	ND	690	24	690	14	690	4	690	14	690	1	690
OPTIDUAL/2016	Aspirin plus clopidogrel ()	40	695	ND	695	16	695	10	695	4	695	14	695	3	695

PEGASUS-TIMI 54/2015	Aspirin ()	632	7067	578	7067	326	7067	210	7067	103	7067	54	7067	ND	7067
	Aspirin plus ticagrelor 60 mg ()	602	7045	487	7045	289	7045	174	7045	78	7045	115	7045	ND	7045
	Aspirin plus ticagrelor 90 mg ()	620	7050	493	7050	326	7050	182	7050	88	7050	127	7050	ND	7050

COMPASS/2015	Aspirin ()	618	8261	460	8261	339	8261	184	8261	120	8261	158	8261	46	8261
COMPASS/2015	Aspirin plus low-dose rivaroxaban ()	610	8313	347	8313	262	8313	139	8313	60	8313	263	8313	50	8313

MACE: major adverse cardiac event; NACE: net adverse clinical event.